Skip to main content
Signal8

NRX Pharmaceuticals, Inc. (NRXP)

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

NRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc.

NASDAQ:NRXPHealthcare
-0.84%$2.36
CLOSED
AH$2.29-2.97%vs close
Mkt Cap$102.18M
Float41.51M
O/S43.3M
VOL498K sh
$ Vol$1.17M
RVOL0.29×
Inst Own28.1%
SI25.2%
Dilution
NRx Pharmaceuticals, Inc. logoNASDAQ:NRXPClosed$2.36-0.84%

NRX Pharmaceuticals, Inc. (NRXP) dilution facts from SEC filings

Snapshot as of Jun 30, 2026, built from 30 SEC filings.

Shelf registration
S-3 filed Jun 20, 2025, effective Dec 22, 2025
Source: 10-Q filed Aug 14, 2026
At-the-market (ATM) program
Yes, sales agreement dated Aug 14, 2023
Source: 10-Q filed Aug 14, 2026
Warrants outstanding
12 warrant series recorded as outstanding
Most recent offering
Public offering, closed Jun 4, 2026
Source: 8-K EX-99.1 filed Aug 17, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro